Highly potent nociceptin analog containing the Arg-Lys triple repeat

被引:71
作者
Okada, K
Sujaku, T
Chuman, Y
Nakashima, R
Nose, T
Costa, T
Yamada, Y
Yokoyama, M
Nagahisa, A
Shimohigashi, Y [1 ]
机构
[1] Kyushu Univ, Fac & Grad Sch Sci, Dept Chem, Lab Struct Funct Biochem, Fukuoka 8128581, Japan
[2] Pfizer Pharmaceut Inc, Cent Res, Aichi 4702393, Japan
[3] Ist Super Sanita, Farmacol Lab, I-00161 Rome, Italy
关键词
nociceptin; nociceptive peptides; opioid peptides; opioid receptors; structure-activity studies; receptor binding;
D O I
10.1006/bbrc.2000.3822
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the structural characteristics of a neuropeptide nociceptin is the existence of Arg-Lys (RK) residues at positions 8-9 and 12-13; both RKs have been suggested to bind to the acidic amino acid cluster in the second extracellular loop of the seven transmembrane domain receptor ORL1. With a design strategy of attempting to obtain an analog that binds moire strongly to the receptor's acidic cluster, we synthesized a series of nociceptin analogs in which the RK dipeptide unit was placed at positions 6-7, 10-11, or 14-15 adjacent to the parent RKs. Among these nociceptin analogs containing the RK triple repeat, [Arg-Lys(6-7)]. and [Arg-Lys(10-11)]nociceptins exhibited weak activities (6-9 and 60-90% of nociceptin, respectively) both in the receptor binding assay and in the [S-35]GTP gammaS binding functional assay. In contrast, [Arg-Lys(14-15)]nociceptin was found to be very potent in both assays (3-fold in binding and 17-fold in GTP gammaS functional assay). [Arg-Lys(14-15)]nociceptin was the first peptide analog found to be stronger than the parent nociceptin, and structure-activity studies have suggested that the incorporated Arg-Lys(14-15) interacts with either the receptor acidic amino acid cluster or the receptor aromatic aminoacidresidues. (C) 2000 Academic Press.
引用
收藏
页码:493 / 498
页数:6
相关论文
共 42 条
[1]  
Albrecht E, 1998, J PHARMACOL EXP THER, V286, P896
[2]   The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics [J].
Barlocco, D ;
Cignarella, G ;
Giardina, GAM ;
Toma, L .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (03) :275-282
[3]   [S-35]GTP gamma S binding: A tool to evaluate functional activity of a cloned opioid receptor transiently expressed in COS cells [J].
Befort, K ;
Tabbara, L ;
Kieffer, BL .
NEUROCHEMICAL RESEARCH, 1996, 21 (11) :1301-1307
[4]   Recognition and activation of the opioid receptor-like ORL1 receptor by nociceptin, nociceptin analogs and opioids [J].
Butour, JL ;
Moisand, C ;
Mazarguil, H ;
Mollereau, C ;
Meunier, JC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (01) :97-103
[5]   Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist [J].
Calo', G ;
Guerrini, R ;
Bigoni, R ;
Rizzi, A ;
Bianchi, C ;
Regoli, D ;
Salvadori, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3360-3366
[6]   DYNORPHIN IS A SPECIFIC ENDOGENOUS LIGAND OF THE KAPPA-OPIOID RECEPTOR [J].
CHAVKIN, C ;
JAMES, IF ;
GOLDSTEIN, A .
SCIENCE, 1982, 215 (4531) :413-415
[7]   SPECIFIC RECEPTOR FOR THE OPIOID PEPTIDE DYNORPHIN - STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
CHAVKIN, C ;
GOLDSTEIN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (10) :6543-6547
[8]   MOLECULAR-CLONING, TISSUE DISTRIBUTION AND CHROMOSOMAL LOCALIZATION OF A NOVEL MEMBER OF THE OPIOID RECEPTOR GENE FAMILY [J].
CHEN, Y ;
FAN, Y ;
LIU, J ;
MESTEK, A ;
TIAN, MT ;
KOZAK, CA ;
YU, L .
FEBS LETTERS, 1994, 347 (2-3) :279-283
[9]   DYNORPHIN1-8 AND DYNORPHIN1-9 ARE LIGANDS FOR THE KAPPA-SUBTYPE OF OPIATE RECEPTOR [J].
CORBETT, AD ;
PATERSON, SJ ;
MCKNIGHT, AT ;
MAGNAN, J ;
KOSTERLITZ, HW .
NATURE, 1982, 299 (5878) :79-81
[10]   SIMULTANEOUS ANALYSIS OF FAMILIES OF SIGMOIDAL CURVES - APPLICATION TO BIOASSAY, RADIOLIGAND ASSAY, AND PHYSIOLOGICAL DOSE-RESPONSE CURVES [J].
DELEAN, A ;
MUNSON, PJ ;
RODBARD, D .
AMERICAN JOURNAL OF PHYSIOLOGY, 1978, 235 (02) :E97-E102